Follow us...

 

Search News Archives

Monthly Newsletter

Lab Bulletin January Newsletter

 

VIEW THE LATEST ISSUE

SUBSCRIBE Here

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

SMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference

RNAi and Nanotechnology Conference

SMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference to be held on 11th &12th June 2012 in London.. This year's event will focus on the utility of nanotechnology to aid the delivery and development of novel therapeutics in the field of RNAi, miRNA and siRNA and senior industry executives will present attendees with in depth studies on targeted exosomes, structure-activity relationships and antisense technologies. 

Key Benefits of Attending:
  • Learn about and consider solutions to the issues within miRNA therapeutic identification and delivery strategies
  • Evaluate Novartis and GSK's innovative strategies to ensure success in effective siRNA delivery 
  • Understand the latest advances in nanotechnology formulation and process engineering from Sanofi-Aventis
  • Hear about antisense developments from RiboBio Pharmaceuticals and the University of Westminster
  • Discuss current developments in novel RNAi therapeutics with experts form Santaris Pharma, Silence Therapeutics and Quark Pharmaceuticals
  • Consider commercialisation and regulatory strategies in nanotechnology
  • Network with key industry professionals and forge partnerships with key players in the field

HEAR KEY PRESENTATIONS FROM EXPERTS IN THE FIELD:

  • Structure-activity relationships of chitosan/siRNA nanoparticles in-vitro and vivo  Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research & Development, Novartis
  • Nanotech formulation and process engineering Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis
  • Non-viral delivery of self-amplifying RNA vaccines Andrew Geall, Platform Technology Leader, Novartis
  • Human mRNA and miRNA expression profiling following a major skin trauma Paul Wilson, Senior Investigator, GlaxoSmithKline
  • RNAi and antisense technologies Dmitry Samarsky, Executive Vice President, RiboBio Pharmaceuticals 

For more information click here. Alternatively contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

Quote "Lab Bulletin" to receive £100 discount!!


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 

 

Media Partners